287 related articles for article (PubMed ID: 20717480)
1. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.
Cooper O; Ben-Shlomo A; Bonert V; Bannykh S; Mirocha J; Melmed S
Horm Cancer; 2010 Apr; 1(2):80-92. PubMed ID: 20717480
[TBL] [Abstract][Full Text] [Related]
2. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.
Langlois F; Lim DST; Yedinak CG; Cetas I; McCartney S; Cetas J; Dogan A; Fleseriu M
Pituitary; 2018 Feb; 21(1):32-40. PubMed ID: 29032459
[TBL] [Abstract][Full Text] [Related]
3. Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas.
Ioachimescu AG; Eiland L; Chhabra VS; Mastrogianakis GM; Schniederjan MJ; Brat D; Pileggi AV; Oyesiku NM
Neurosurgery; 2012 Aug; 71(2):296-303; discussion 304. PubMed ID: 22517250
[TBL] [Abstract][Full Text] [Related]
4. Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases.
Zhang K; Shou X; Chen H; Qiao N; He W; Chen Z; Shen M; Li S; Zhao Y; Zhang Z; Li Y; Ye H; Wang Y
Front Endocrinol (Lausanne); 2020; 11():608691. PubMed ID: 33584540
[TBL] [Abstract][Full Text] [Related]
5. Silent corticotroph adenomas.
Ben-Shlomo A; Cooper O
Pituitary; 2018 Apr; 21(2):183-193. PubMed ID: 29344907
[TBL] [Abstract][Full Text] [Related]
6. Silent corticotroph adenomas.
Cooper O
Pituitary; 2015 Apr; 18(2):225-31. PubMed ID: 25534889
[TBL] [Abstract][Full Text] [Related]
7. Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system.
Jiang S; Zhu J; Feng M; Yao Y; Deng K; Xing B; Lian W; Wang R; Bao X
Pituitary; 2021 Aug; 24(4):564-573. PubMed ID: 33651318
[TBL] [Abstract][Full Text] [Related]
8. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.
Nishioka H; Inoshita N; Mete O; Asa SL; Hayashi K; Takeshita A; Fukuhara N; Yamaguchi-Okada M; Takeuchi Y; Yamada S
Endocr Pathol; 2015 Dec; 26(4):349-55. PubMed ID: 26481628
[TBL] [Abstract][Full Text] [Related]
9. Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas.
Kim D; Ku CR; Park SH; Moon JH; Kim EH; Kim SH; Lee EJ
World Neurosurg; 2018 Jul; 115():e464-e471. PubMed ID: 29678704
[TBL] [Abstract][Full Text] [Related]
10. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.
Raverot G; Wierinckx A; Jouanneau E; Auger C; Borson-Chazot F; Lachuer J; Pugeat M; Trouillas J
Eur J Endocrinol; 2010 Jul; 163(1):35-43. PubMed ID: 20385723
[TBL] [Abstract][Full Text] [Related]
11. Clinical Relevance and Immunohistochemical Patterns of Silent Pituitary Adenomas: 10 Years of Single-centre Experience.
Akkus G; Karagun B; Çetinalp NE; Açıkalın A; Evran M; Sengöz S; Sert M; Zorludemir S; Tetiker T
Curr Med Imaging; 2021; 17(2):310-317. PubMed ID: 33357196
[TBL] [Abstract][Full Text] [Related]
12. Clinical, Laboratory, and Treatment Profiles of Silent Corticotroph Adenomas That Have Transformed to the Functional Type: A Case Series With a Literature Review.
Zheng G; Lu L; Zhu H; You H; Feng M; Liu X; Dai C; Yao Y; Wang R; Zhang H; Sun X; Lu Z
Front Endocrinol (Lausanne); 2020; 11():558593. PubMed ID: 33071973
[No Abstract] [Full Text] [Related]
13. The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.
Mete O; Hayhurst C; Alahmadi H; Monsalves E; Gucer H; Gentili F; Ezzat S; Asa SL; Zadeh G
Endocr Pathol; 2013 Dec; 24(4):191-8. PubMed ID: 24091601
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of microcystic aspect on T2-weighted MRI for the diagnosis of silent corticotroph adenomas.
Kasuki L; Antunes X; Coelho MCA; Lamback EB; Galvão S; Silva Camacho AH; Chimelli L; Ventura N; Gadelha MR
Clin Endocrinol (Oxf); 2020 Feb; 92(2):145-149. PubMed ID: 31773787
[TBL] [Abstract][Full Text] [Related]
15. Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence.
Strickland BA; Shahrestani S; Briggs RG; Jackanich A; Tavakol S; Hurth K; Shiroishi MS; Liu CJ; Carmichael JD; Weiss M; Zada G
J Neurosurg; 2021 May; 135(6):1706-1713. PubMed ID: 33962375
[TBL] [Abstract][Full Text] [Related]
16. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas.
Cho HY; Cho SW; Kim SW; Shin CS; Park KS; Kim SY
Clin Endocrinol (Oxf); 2010 May; 72(5):648-53. PubMed ID: 19650787
[TBL] [Abstract][Full Text] [Related]
17. Silent corticotroph adenomas after stereotactic radiosurgery: a case-control study.
Xu Z; Ellis S; Lee CC; Starke RM; Schlesinger D; Lee Vance M; Lopes MB; Sheehan J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):903-10. PubMed ID: 25216855
[TBL] [Abstract][Full Text] [Related]
18. UPLC-MS/MS-based Lipidomic Profiles Revealed Aberrant Lipids Associated with Invasiveness of Silent Corticotroph Adenoma.
Wang Z; Guo X; Wang W; Gao L; Bao X; Feng M; Lian W; Zhu H; Xing B
J Clin Endocrinol Metab; 2021 Jan; 106(1):e273-e287. PubMed ID: 33031533
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [Review].
Kageyama K; Oki Y; Nigawara T; Suda T; Daimon M
Endocr J; 2014; 61(10):941-8. PubMed ID: 24974880
[TBL] [Abstract][Full Text] [Related]
20. ACTH and alpha-subunit are co-expressed in rare human pituitary corticotroph cell adenomas proposed to originate from ACTH-committed early pituitary progenitor cells.
Suzuki M; Egashira N; Kajiya H; Minematsu T; Takekoshi S; Tahara S; Sanno N; Teramoto A; Osamura RY
Endocr Pathol; 2008; 19(1):17-26. PubMed ID: 18228160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
